gadopentetate dimeglumine


Also found in: Wikipedia.

gadopentetate dimeglumine

 [gad″o-pen´tĕ-tāt di-meg´loo-mēn]
a paramagnetic agent used as a contrast agent in magnetic resonance imaging of intracranial, spinal, and associated lesions.

gadopentetate dimeglumine

/gad·o·pen·te·tate di·meg·lu·mine/ (gad″o-pen´tĕ-tāt di-meg´loo-mēn) a paramagnetic agent used as a contrast agent in magnetic resonance imaging of intracranial, spinal, and associated lesions.
References in periodicals archive ?
Closely related diagnostic agents are gadobenate dimeglumine (MultiHance), gadodiamide (Omniscan), gadofosveset (Ablavar), gadopentetate dimeglumine (Magnevist), gadoteridol (Prohance), and gadoversetamide (OptiMARK).
In recent two years, as for the drug procurement in 22 cities in China, there were six major varieties of contrast media, namely, iohexol, iopromide, gadopentetate dimeglumine, iopamidol, ioversol and meglumine diatrizoate, of which the former three varieties were listed among the best-selling 200 drugs.
For contrast imaging, T1-weighted FLAIR sequences also were obtained after administration of gadopentetate dimeglumine (0.
Patients At higher risk * Patients with CKD 4 and 5 (GFR < 30 ml/min) * Patients on dialysis * Patients with acute kidney insufficiency At lower risk * Patients with CKD 3 (GFR 30 - 59 ml/min) Not at risk of NSF * Patients with stable GFR > 60 ml/min) Highest risk of NSF Gadopentetate dimeglumine (Magnevist plus generic products) Gadodiamide (Omniscan) Gadoversetamide (Optimark) Recommendations for These agents are CONTRA-INDICATED high-risk group in: * patients with CKD 4 and 5 (GFR <30 ml/min), including those on dialysis * acute renal insufficiency * pregnant women * neonates These agents should be used with CAUTION in: * patients with CKD 3 (GFR 30 - 60 ml/min) * There should be at least 7 days between 2 injections.
Dynamic sequences were obtained before and after a standard 20-mL gadopentetate dimeglumine (Magnevist, Bayer HealthCare Pharmaceuticals, Inc.
The contract is for delivery of contrast agents, including the following packages: Package # 1 1) Gadopentetate dimeglumine 2) Gadobutrol 3) Iopromide Package No.
1 mmol/kg intravenous gadopentetate dimeglumine contrast agent, coronal fat-suppressed T1-weighted SE (TR 656 ms, TE 12 ms, slice thickness 3 mm, matrix 154x256, acquisitions 2) images, were acquired.
A 15 milliliter of diluted gadopentetate dimeglumine (Magnevist; Schering, Berlin, Germany) syringe was prepared with a concentration of 2 mmol/1.
Currently, there are four gadolinium-based contrast agents available commercially in the U5: gadodiamide (Omniscan; Amersham Health), gadopentetate dimeglumine (Magnevist; Schering), gadoversetamide (OptiMARK; Mallinckrodt Medical), and gadoteridol (Prohance; Bracco).
Magnetic resonance imaging, post IV gadopentetate dimeglumine, demonstrated a destructive lesion of the head of the fibula surrounded by a fluid collection with enhancing rim, raising the possibility of an abscess (Figs.